Clinical Trials Logo

Clinical Trial Summary

The Conscious Dying/Conscious Living study will investigate the effect of KAP (ketamine-assisted psychotherapy) on individuals with terminal illness at five separate geographic locations. Two separate IM ketamine sessions will be administered to 18 subjects at each site, with psychotherapeutic support, including preparatory and integrative sessions. Assessments will be administered throughout the course of the protocol, which will take 4-6 weeks to complete, and the primary outcome measures are changes in the STAI (State-trait Anxiety Inventory, trait assessment only) and the DADDS (Death and Dying Distress Scale) from baseline at the beginning of the study to the conclusion of the treatment period. A six-subject naturalistic comparator group at each site will complete the same assessments without intervention, and then will be offered an optional crossover KAP treatment.

Clinical Trial Description


Study Design

NCT number NCT05214417
Study type Interventional
Source The Ketamine Research Foundation
Contact Philip E Wolfson, MD
Phone 415-550-1700
Status Not yet recruiting
Phase Phase 2
Start date May 1, 2022
Completion date March 31, 2024